Onivyde is a liposomal formulation of irinotecan, a topoisomerase I inhibitor [1]. This formulation involves encapsulating irinotecan within tiny lipid spheres, known as liposomes [1]. The liposomal delivery system is designed to alter the pharmacokinetic profile of irinotecan, potentially improving its efficacy and managing its toxicity [2].
How does the Onivyde liposomal formulation affect how the drug works?
The liposomal encapsulation of irinotecan in Onivyde is intended to control the release of the active drug [1]. This controlled release can influence how the drug is distributed in the body and how long it remains active, which is crucial for its anti-cancer effects [2]. By modifying irinotecan's pharmacokinetics, the liposomal formulation aims to enhance its delivery to tumor sites while potentially reducing exposure to healthy tissues, thereby managing side effects [2].
What is irinotecan, and how does it fight cancer?
Irinotecan is a chemotherapy drug that works by inhibiting topoisomerase I [1]. This enzyme is essential for DNA replication and repair in cancer cells. By blocking topoisomerase I, irinotecan causes damage to the cancer cell's DNA, ultimately leading to cell death [1].
When does Onivyde's patent protection expire?
Information regarding the specific patent expiry dates for Onivyde's formulation is available through specialized patent tracking services [3]. These services monitor the intellectual property landscape for pharmaceuticals, including patent lifespans and any challenges or extensions that may affect market exclusivity [3]. DrugPatentWatch.com provides such data for various drug products, including their formulations [3].
What are the potential risks associated with Onivyde?
As with any chemotherapy, Onivyde carries risks of side effects. These can include myelosuppression (low blood cell counts), diarrhea, nausea, vomiting, and fatigue [2]. The liposomal formulation is designed to potentially mitigate some of these, but careful monitoring by a healthcare professional is necessary [2].